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CO-TRANSPLANTATION OF HLA-MATCHED RELATED DONORS CULTURE-
EXPANDED MESENCHYMAL STROMAL CELLS AND HEMATOPOIETIC
STEM CELLS IN THALASSEMIA MAJOR PATIENTS
Ghavamzadeh, A., Alimoghaddam, K., Hamidieh, A.A., Karimi, A.,
Bashtar, M., Shamshiri, A.R. Tehran University of Medical Sciences,
Tehran, Islamic Republic of Iran
Objective:Use of mesenchymal stromal cells (MSCs) in hematopoi-
etic stem cell transplantation (HSCT), either for enhancement of he-
matopoietic engraftment or for prevention of graft versus host
disease (GVHD) is currently unknown. Following a positive phase
II study in all classes of thalassemia major, in this study we aimed
to show that co-transplantation of MSC and hematopoietic stem
cells (HSCs) from HLA-matched related donors after conditioning
regimen is safe and could facilitate engraftment and decrease
GVHD.
Methods: Between November 2006 and October 2009, 48 class
III thalassemia major patients were enrolled. In this double-blind
randomized clinical trial, HLA-identical related donors HSC
were transplanted (non-MSCs group, n5 23 with median age
of 16yrs and F/M5 11/12) or co-transplanted with MSCs
(MSCs group, n5 25 with median age of 17yrs and F/M5 8/
17) in thalassemia major patients. Patients received Cyclophos-
phamide-based or Fludarabine-based conditioning regimens and
short course methotrexate and cyclosporine as GVHD prophy-
laxis. On day 0, MSCs group patients were given MSCs intrave-
nously 4 hours before infusion of either bone marrow or
peripheral blood stem cells. The number of MSCs infused was
1.45-1.8010^6/kg.
Results: MSCs infusions were well tolerated. The median time to
neutrophil engraftment (absolute neutrophil count .0.510^9/L)
was 14 days for MSCs group and 13 days for non-MSCs group (p-
value5 0.16). The median time to platelet engraftment (platelet
count .2010^9/L) was 16 and 15 days, respectively (p-val-
ue5 0.34). Acute GVHD grade III-IV was observed respectively,
in 6(24%) and 4(17.5%). (p-value5 0.73). Median follow-up dura-
tion for alive patients was 10 months (ranged 1-28).
Conclusion: In this study we demonstrated that co-transplantation
of HLA-matched related donors MSCs with HSCs is seems to be
safe. We didn’t find statistical significant difference in acute
GVHD incidence, rate of non-engraftment, mortality rate and me-
dian time to neutrophil and platelet recovery between two groups.
Most probably explanations are small number of patients in study
groups and short follow-up period.151
STROMAL ELEMENTS AND ENGRAFTMENT IN AUTOLOGOUS HEMATO-
POIETIC PROGENITOR CELL (HPC) TRANSPLANT FOR MYELOMA
Veeraputhiran,M.1, Singh, Z.1, Barlogie, B.2, Cottler-Fox,M.1 1Univer-
sity of Arkansas for Medical Sciences, Little Rock, AR; 2Myeloma Institute
for Research & Therapy, Little Rock, AR
Introduction: Homing of HPC after transplant may be related to
stromal elements of the hematopoetic stem cell niche. We present
a retrospective analysis of bone marrow (BM) biopsies from patients
with myeloma prior to autologous HPC transplant and correlate
stromal variables with engraftment.
Material andMethods: 25 consecutive patients who underwent au-
tologousHPC transplant and survived 100 days post-transplant were
identified. BM biopsies done just prior to transplant were analyzed
using hematoxylin and eosin stained sections to evaluate the follow-
ing histological parameters: stromal components (fat, regenerating
adipocytes, fat necrosis, stromal edema, vasculature and stromal
hemorrhage); bone remodeling (osteoblasts vs osteoclasts); hemato-
poeisis (endosteal vs peri-sinusoidal hematopoesis); cellularity; and
interstitial fibrosis. Disease specific parameters including duration
of disease before transplant, conditioning therapy for transplant,
and total viable CD34 stem cells infused for transplant were also
identified. Time to platelet engraftment of 20,000/cmm and
50,000/cmm and time to WBC engraftment (ANC $500/cmm)
were determined. Univariate and multivariate regression analysis
were applied to determine, in a step-wise fashion, the correlationof independently significant BM stromal parameters with engraft-
ment.
Results: The median time to platelet engraftment of 20,000/cmm
and 50,000/cmm were 12 and 16 days respectively. The median
time to WBC engraftment was 11 days. Sinusoidal hematopoesis
was significantly correlated with delayed platelet engraftment to
20,000 ($ 12 days) (p5 0.034). Stromal edema correlated with de-
layedWBC engraftment ($ 11 days) (p5 0.042). No other variables
examined were statistically significant.
Conclusion: Pretransplant BM biopsy evaluation for stromal in-
jury as demonstrated by stromal edema and peri-sinusoidal hema-
topoiesis may be useful markers for predicting delayed platelet
and WBC engraftment in patients undergoing HPC transplant
for myeloma.152
MESENCHYMAL STEM CELLS: HEALTHY AT ANY AGE
Lund, T.C., Kobs, A., Blazar, B.R., Tolar, J. University of Minnesota,
Minneapolis, MN
Mesenchymal Stem Cells (MSC) are gaining in popularity as
an experimental therapy for a number of conditions including
graft-versus-host disease, Crohn’s disease, myocardial infarction,
etc. Most applications require that MSCs be expanded to achieve
an adequate cell-dose for therapy. Prior data suggest that MSC
undergo aging in culture and that MSC from older donors un-
dergo earlier senescence than MSC from younger donors. We
have observed over 100 MSC expansion cultures and it seemed
that early in the expansion period MSC from any age donor mi-
croscopically appeared healthy and showed no difference upon
differentiation into adipogenic, osteogenic, or cartilage lineages.
We hypothesized that MSC from any age donor would have sim-
ilar cellular fitness when expanded under incubation conditions
and limited passage to mimic cell handling that would be used
in a clinical preparation. We have compared the expression of
several markers of aging in MSCs obtained from a subset of
120 donors over a wide range of ages (8 months to 60 years).
We find that although MSC from older individuals produced
slightly fewer cells over a fixed number of passages and have
a slightly longer doubling time (54 hrs vs 42 hrs), a satisfactory
clinical product can still be obtained (multiple doses at .106
cell/kg). When MSC from young (0.8-6 years) and old (43-60
years) were compared there was no difference in cell surface
markers, lipofuscin, migration ability, or expression of aging
markers such as iNOS, PGE2, p16, and SOD. SOD activity
(0.025 vs 0.028 U/ml) and oxidative challenge death rate to hy-
drogen peroxide were not significantly different (1% vs 1.5%,
p5 0.14). Morphology by light microscopy and extent of qualita-
tive differentiation into osteogenic, adipogenic, and cartilage cell
types were also similar in old and young donor derived MSC. Fi-
nally, telomeres did not show a significant difference in length
between young and old donor-derived MSC early in passage.
We conclude that age may not need to be considered when de-
termining a potential MSC donor especially in light of the fact
that many clinical applications require only a limited culture
time (19-21 days) to achieve a sufficient number of cells for a use-
ful clinical product.153
AFRICAN AMERICAN ADULT DONORS RESPOND TO G-CSF WITH PRO-
GENITOR CELL YIELDS COMPARABLE TO CAUCASIAN AND HISPANIC DO-
NORS
Carilli, A.R.1, Sugrue, M.W.1, Chang, M.1, Fisk, D.2, Medei, M.2,
Williams, K.2, Wiggins, L.2, Wingard, J.R.1 1University of Florida,
Gainesville, FL; 2Shands Hospital at the University of Florida, Gaines-
ville, FL
Background: Because African Americans (AAs) have lower leuko-
cyte counts and cord bloods fromAA neonates have fewer progenitor
cells, we examined the responses toG-CSF and progenitor cell yields
in healthy adult AAs.
